Agentic AI for Pharma Launches: Access & Engagement
Agentic AI can enhance pharma launches by improving market access and HCP engagement, with potential efficiency gains of up to 80%.
- Publisher
- IntuitionLabs
- Published
- Length
- 16 pages
- File
- 506 KB PDF
Download the full 16-page PDF
Free · 506 KB · Instant access after email
This whitepaper explores the transformative potential of agentic AI in pharmaceutical commercial launches, emphasizing its ability to enhance market access and HCP engagement.
- Agentic AI can reduce evidence synthesis time by ~80%.
- AI-driven omnichannel strategies can increase field sales impact by 14%.
- 95% of pharma firms are investing in AI, with $25 billion projected by 2030.
- Challenges to adoption include compliance and cultural hurdles.
- Proactive integration of AI is essential for competitive advantage.
Ready to read the full report?
Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.
More whitepapers like this
Strategies to Enhance Recruitment of Female Participants to Cardiovascular Research
This consensus document outlines strategies to increase female representation in cardiovascular clinical trials, addressing significant under-representation of women.
British Society of Gastroenterology Guidelines on Inflammatory Bowel Disease in Adults: 2025
The updated BSG guidelines emphasize the necessity of ileocolonoscopy for IBD diagnosis and advocate for immunomodulators in all patients.
🔒 The Patient Confusion Crisis
Pharma faces a $5B crisis as 35-40% of patients abandon specialty prescriptions. Misinformation from social media is eroding treatment adherence.